Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ticalopride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 13/20 | 0.85 |
| ▸ | HTR3A | P46098 | 4/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.52 |
| ▸ | HTR3B | O95264 | 1/20 | 0.52 |
| ▸ | HTR5A | P47898 | 1/20 | 0.52 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.52 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ticalopride SCHEMBL17208 | 0.92 | HTR4 (1.00) | HTR4HTR3AMAPK1HTR3EHTR3B | |
| Norcisapride SCHEMBL593405 | 0.92 | HTR4 (1.00) | HTR4HTR3AMAPK1HTR3EHTR3B | |
| Norcisapride SCHEMBL734363 | 0.92 | HTR4 (1.00) | HTR4HTR3AMAPK1HTR3EHTR3B | |
| Norcisapride SCHEMBL3317329 | 0.92 | HTR4 (1.00) | HTR4HTR3AMAPK1HTR3EHTR3B | |
| Norcisapride SCHEMBL8245159 | 0.92 | HTR4 (1.00) | HTR4HTR3AMAPK1HTR3EHTR3B | |
| Norcisapride SCHEMBL3319911 | 0.92 | HTR4 (1.00) | HTR4HTR3AMAPK1HTR3EHTR3B | |
| SCHEMBL9790000 | 0.89 | HTR4 (0.92) | HTR4HTR3AMAPK1HTR3EHTR3B | |
| SCHEMBL9789995 | 0.89 | HTR4 (0.92) | HTR4HTR3AMAPK1HTR3EHTR3B | |
| SCHEMBL9789990 | 0.89 | HTR4 (0.92) | HTR4HTR3AMAPK1HTR3EHTR3B | |
| Water SCHEMBL9721747 | 0.84 | HTR4 (0.80) | HTR4HTR3AMAPK1HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176414-A1 | (+)-Norcisapride | HEYKANTS JOZEF JAN PIETER (BE) | 2004-09-09 | — | — | US | disclosed |
| EP-1000029-B1 | (+)-NORCISAPRIDE USEFUL FOR 5-HT3 AND 5-HT4 MEDIATED DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2003-10-01 | — | — | EP | disclosed |
| US-20030060485-A1 | (+)-norcisapride | HEYKANTS JOZEF JAN PIETER (BE) | 2003-03-27 | — | — | US | disclosed |
| EP-1000029-A1 | (+)-NORCISAPRIDE USEFUL FOR 5-HT3 AND 5-HT4 MEDIATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002496-A1 | (+)-NORCISAPRIDE USEFUL FOR 5-HT3 AND 5-HT4 MEDIATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176414-A1 | (+)-Norcisapride | SI, GIPR, SLC10A2 | HTR4 93/4885HTR3A 194/4885MAPK1 3028/4885 |
| US-20030060485-A1 | (+)-norcisapride | SI, GIPR, SLC10A2 | HTR4 93/4885HTR3A 194/4885MAPK1 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.